Mark Sawicki Biography and Net Worth

Insider of Cryoport

Mark Sawicki brings 15 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Sawicki was most recently the chief business officer at AAIPharma Services Corporation/Cambridge Major Laboratories Inc. Additionally, he has served in senior business development roles at CMC Biologics and Albany Molecular Research Inc. (AMRI), where he increased revenue at rates far outpacing industry standards. Sawicki holds a bachelor’s in biochemistry from the State University of New York at Buffalo and a Ph.D. in biochemistry from the State University of New York at Buffalo, School of Medicine and Biomedical Sciences. He also received graduate training at the Hauptman Woodard Medical Research Institute. Sawicki has authored a dozen scientific publications in drug discovery with a focus on oncology and immunology.

What is Mark W. Sawicki's net worth?: The estimated net worth of Mark W. Sawicki is at least $601,222.05 as of March 24th, 2025. Dr. Sawicki owns 84,087 shares of Cryoport stock worth more than $601,222 as of May 12th. This net worth approximation does not reflect any other investments that Dr. Sawicki may own. Learn More about Mark W. Sawicki's net worth.
How do I contact Mark W. Sawicki?: The corporate mailing address for Dr. Sawicki and other Cryoport executives is 112 Westwood Place Suite 350, Brentwood TN, 37027. Cryoport can also be reached via phone at (949) 470-2300 and via email at [email protected]. Learn More on Mark W. Sawicki's contact information.
Has Mark W. Sawicki been buying or selling shares of Cryoport?: Mark W. Sawicki has not been actively trading shares of Cryoport during the last quarter. Most recently, Mark W. Sawicki sold 1,349 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $6.94, for a transaction totalling $9,362.06. Following the completion of the sale, the insider now directly owns 84,087 shares of the company's stock, valued at $583,563.78. Learn More on Mark W. Sawicki's trading history.
Who are Cryoport's active insiders?: Cryoport's insider roster includes Richard Berman (Director), Daniel Hancock (Director), Mark Sawicki (Insider), Jerrell Shelton (CEO), Robert Stefanovich (CFO), and Edward Zecchini (Director). Learn More on Cryoport's active insiders.
Are insiders buying or selling shares of Cryoport?: During the last twelve months, insiders at the sold shares 19 times. They sold a total of 148,414 shares worth more than $1,069,109.51. The most recent insider tranaction occured on March, 24th when insider Mark W Sawicki sold 1,349 shares worth more than $9,362.06. Insiders at Cryoport own 10.0% of the company. Learn More about insider trades at Cryoport.
Information on this page was last updated on 3/24/2025.

Mark W. Sawicki Insider Trading History at Cryoport

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2025	Sell	1,349	$6.94	$9,362.06	84,087
3/10/2025	Sell	1,583	$4.88	$7,725.04	78,528
3/25/2024	Sell	1,367	$17.54	$23,977.18	77,444
3/15/2024	Sell	1,312	$15.43	$20,244.16	73,061
3/11/2024	Sell	1,418	$16.35	$23,184.30	74,373
3/15/2023	Sell	1,362	$20.79	$28,315.98	61,670
3/13/2023	Sell	1,476	$20.14	$29,726.64	63,032
3/9/2022	Sell	1,410	$31.05	$43,780.50
3/10/2021	Sell	13,331	$55.13	$734,938.03	30,342

Mark W. Sawicki Buying and Selling Activity at Cryoport

Cryoport Company Overview

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Today's Range

Now: $7.15

$6.93

$7.52

50 Day Range

MA: $5.88

$4.70

$7.10

2 Week Range

Now: $7.15

$4.58

$14.21

Volume

785,507 shs

Average Volume

542,962 shs

Market Capitalization

$358.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92